Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial.
Ominelli J, Araujo ROC, Valadão M, Padoan MLA, Lopes Dos Santos VM, Dutra JG, Torres CC, Barbosa MA, Guimarães R, Carvalho JCC, Ferreira MA, de Oliveira IM, Small I, de Melo AC, Araujo LH. Ominelli J, et al. Among authors: de melo ac, de oliveira im. Clin Colorectal Cancer. 2022 Sep;21(3):e196-e204. doi: 10.1016/j.clcc.2022.05.002. Epub 2022 May 13. Clin Colorectal Cancer. 2022. PMID: 35668002 Clinical Trial.
A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.
de Melo AC, Paulino E, Garces ÁH. de Melo AC, et al. Oxid Med Cell Longev. 2017;2017:4809751. doi: 10.1155/2017/4809751. Epub 2017 Feb 13. Oxid Med Cell Longev. 2017. PMID: 28286604 Free PMC article. Review.
Panorama of Gynecologic Cancer in Brazil.
Paulino E, de Melo AC, Silva-Filho AL, Maciel LF, Thuler LCS, Goss P, Nogueira-Rodrigues A. Paulino E, et al. Among authors: de melo ac. JCO Glob Oncol. 2020 Oct;6:1617-1630. doi: 10.1200/GO.20.00099. JCO Glob Oncol. 2020. PMID: 33108231 Free PMC article.
128 results